Aer Lingus owner announces major Boeing and Airbus jet deals
There's also an option to top up the deal with as many as 10 additional Boeing 787s and up to 13 additional Airbus A330neos, IAG said.
The Boeing element of the deal had been flagged by the US as a win in the context of this week's UK:US trade agreement.
On Friday Aer Lingus reported an operating loss of €55m for the first quarter of 2025, compared to an €82m operating loss in the same three months of 2024.
The first three months are typically the weakest quarter of the year for the airline, Aer Lingus's CEO, Lynne Embleton said the performance represents a strong financial outcome and a significant improvement on Q1 2024 and flagged new aircraft entering service with the fleet.
"The Q1 performance builds upon the underlying momentum seen in the business from 2024. The first two of six A321 XLR aircraft are now in service and operating on our new routes to Nashville and Indianapolis. These new aircraft and the remaining four XLRs which are expected to join the fleet later this year will support a compelling growth ambition that will benefit the airline, our customers, our employees and the economy.'
IAG's first-quarter adjusted operating profit rose to €198m , beating the estimates amid lower fuel prices and higher revenue.
Despite some evidence of softening traveller interest in the US market this year the company maintained its outlook, saying it is "continuing to see good demand for air travel across our core markets and for our brands."
Bloomberg News reported on Thursday that Boeing was poised to win an order from IAG, in a deal tied to US President Donald Trump's new trade agreement with the UK. The Boeing portion of the accord marks a political win for Trump, whose tariff barrage has shaken global markets and tested the strong outlook for transatlantic routes that have bolstered major airlines such as BA.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
RTÉ News
an hour ago
- RTÉ News
Trump says he will use import restrictions to reduce drug prices
US President Donald Trump said he would use import restrictions to force foreign suppliers to cut drug prices and that pharmaceutical companies would have a lot of problems if they did not agree to bring prices down. Speaking at the White House at an event with Republican politicians, Mr Trump pledged to reduce what consumers must pay for prescription drugs. The US is the biggest market by sales for big pharma companies, and Europe and the US have interconnected supply chains for medicines with the pharmaceutical sector employing around 45,000 people in Ireland. Total Irish exports were valued at €223.8 billion last year, with roughly one third going to the US. Of the €72.6 billion in US imports from Ireland, approximately €58 billion relates to pharmaceuticals and chemicals leaving Ireland. Pharmaceutical companies have previously expressed concern about the threat of tariffs and what they would mean for investment in Europe. In April, a number of pharmaceutical companies sent a letter to EU Commission President Ursula von der Leyen, warning that the EU could lose €100bn in new investment unless there is a rethinking on regulation and pricing. The letter was sent by around 30 CEOs of some of the largest pharmaceutical companies in the world.
Irish Examiner
4 hours ago
- Irish Examiner
Davy to focus more investment on European markets amid volatility in US
Despite the fallout from US president Donald Trump's trade war being 'much milder' than expected, Irish wealth management firm Davy still plans to 'bias away' from US markets as high valuations make it 'more vulnerable to correction if the economic picture changes'. In the firm's latest Wealth View report for the third quarter of the year, it noted that US equity markets have rebounded from the turbulence caused by Mr Trump's tariff announcement on April 2 and that Europe has shown strength with markets across the bloc ahead of where they were last year. It attributed the rebound in the US markets to investor confidence that the administration would retreat from policies that disrupt the market, and by optimism surrounding the stimulative effects of the One Big Beautiful Bill Act passed recently by the US Congress. The report said that the economic fallout from the trade war has been 'much milder' than expected 'as tariffs have been paused or have yet to make an impact'. 'Unfortunately, the better-than-expected news is mostly factored into equity valuations already, which have recovered rapidly to multi-year highs, led by the US and the tech sector,' the report said. We note that high valuations are not enough to move markets on their own, but they do make a market more vulnerable to correction if the economic picture changes. "For this reason, we maintain our bias away from the US and towards Europe and emerging markets.' Davy said that the eurozone and China are currently doing better than forecasted but the UK remains in a tight spot. The rising value of the euro against the dollar has also been a significant development for investors this year, according to Davy. However, it cautioned that too strong a euro could cause issues for the European Central Bank (ECB). 'A weaker dollar will push up prices in the US just when tariffs may be doing the same. Also, foreign central banks may push back if the exchange rate interferes with their mandates. For example, the ECB has identified €1.20 as a threshold for concern for the euro-dollar exchange rate,' the report said. The report said that while the S&P 500 hit new highs in June, it has delivered negative returns, after accounting for the depreciation of the dollar. In the first half of the year, the European Stoxx 600 index beat the S&P 500 by the biggest margin this century. Chief investment officer at Davy, Donough Kilmurray, said the last six months show the importance of diversification across investment portfolios. 'We are investing through a period of unusually high uncertainty, and all sorts of assets have played a role already this year, from less-favoured equities to alternative strategies to gold, both by adding to returns and by cushioning declines,' he said. 'Given the incumbent in the White House, we intend to stay diversified.' In a bid to protect against this volatility, Davy has made changes to its Strategic Asset Allocation (SSA) which shifts how it manages long-term portfolios. These include reducing equity exposure in cautious and moderate portfolios, increasing allocation to bonds to help protect against market volatility and macroeconomic risks, as well as increasing the use of alternative investments, including hedge fund-style strategies and gold. Read More Irish economy to grow by more than 4% through 2027 despite heightened geopolitical tensions
Irish Examiner
4 hours ago
- Irish Examiner
AstraZeneca says new facility in Dublin on target for 2026 completion
Drug maker AstraZeneca has announced plans to invest $50bn (€42.6bn) in the US over the next five years amid the looming threat of US president Donald Trump's trade tariffs. The firm said the investment will fund a new "state-of-the-art" manufacturing facility in Virginia - set to be its largest single manufacturing investment in the world. It will also expand research and development (R&D) and cell therapy manufacturing in Maryland, Massachusetts, California, Indiana and Texas. In 2021 AstraZeneca said it was investing €300m to establish a next-generation active pharmaceutical ingredient (API) manufacturing facility for small molecules in Dublin. Those plans are unaffected by the US announcement, a spokesperson told the Irish Examiner. "In line with our plans, the construction of our synthetic drug substance commercialisation facility in Ireland is scheduled for completion in 2026," said the spokesperson. The US announcement marks the latest by a global pharmaceutical giant to expand its footprint in the US as Mr Trump has threatened to impose tariffs of up to 20% on drug imports in an effort to increase manufacturing in America and drive down costs for Americans. AstraZeneca said the mammoth investment will create tens of thousands of jobs across the US, "powering growth and delivering next-generation medicines for patients in America and worldwide". The Anglo-Swedish group, which is listed on the FTSE 100, said the investment will also help it towards the group's target of reaching $80bn (€60bn) in revenues by 2030, with half of this is expected to come from the US, it added. Despite being headquartered in the UK, America is AstraZeneca's largest market, where it employs more than 18,000 staff and makes 42% of total group sales. It already has 19 R&D, manufacturing and commercial sites across the country.
